Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Oct;21(5):397-408.
doi: 10.1007/s40272-019-00353-7.

DTaP-IPV-HepB-Hib Vaccine (Hexyon®): An Updated Review of its Use in Primary and Booster Vaccination

Yahiya Y Syed  1
Affiliations
Review

DTaP-IPV-HepB-Hib Vaccine (Hexyon®): An Updated Review of its Use in Primary and Booster Vaccination

Yahiya Y Syed. Paediatr Drugs. 2019 Oct.

Erratum in

Abstract

Hexyon® is a fully-liquid, ready-to-use, hexavalent vaccine approved in the EU since 2013 for primary and booster vaccination in infants and toddlers from age 6 weeks against diphtheria, tetanus, pertussis, hepatitis B (HB), poliomyelitis, and invasive diseases caused by Haemophilus influenzae type b (Hib). While the source of HB antigen in Hexyon® is different from other vaccines, the rest of its valences have been extensively used in other approved vaccines. Hexyon® is highly immunogenic for all its component toxoids/antigens when used as primary and booster vaccine in infants and toddlers, irrespective of vaccination schedule. It provides durable protection against hepatitis B. Hexyon® can be used for a mixed primary series of hexavalent-pentavalent-hexavalent vaccines or as a booster in infants primed with Infanrix hexa™ or pentavalent (whole-cell or acellular pertussis) vaccines. Coadministration of Hexyon® with other common childhood vaccines did not affect immune response to any vaccines. Hexyon® has a good reactogenicity/safety profile. The immunogenicity and safety profile of Hexyon® was similar to that of several approved vaccines, including Infanrix hexa™. However, Hexyon® offers the convenience of full-liquid, ready-to-use formulation, which may minimize vaccination errors and preparation time. Thus, Hexyon® is a convenient, useful option for vaccination against childhood diseases caused by six major pathogens.

PubMed Disclaimer

Conflict of interest statement

Yahiya Syed is a salaried employee of Adis/Springer, is responsible for the article content and declares no relevant conflicts of interest.

Figures

Fig. 1
Fig. 1
Incidence of solicited adverse events occurring within 7 days after any primary vaccination in Hexyon® (n  = 1030) and Infanrix hexa™ (n  = 345) recipients in a representative study (A3L24) [10]. HEX Hexyon®, IFX Infanrix hexa™
See this image and copyright information in PMC

References

    1. Obando-Pacheco P, Rivero-Calle I, Gomez-Rial J, et al. New perspectives for hexavalent vaccines. Vaccine. 2018;36(36):5485–5494. - PubMed
    1. Vidor E, Soubeyrand B. Manufacturing DTaP-based combination vaccines: industrial challenges around essential public health tools. Expert Rev Vaccines. 2016;15(12):1575–1582. - PubMed
    1. European Medicines Agency. Hexyon suspension for injection: summary of product characteristics. 2013. https://www.ema.europa.eu. Accessed 10 Jun 2019.
    1. McCormack PL. DTaP-IPV-Hep B-Hib vaccine (Hexaxim®): a review of its use in primary and booster vaccination. Paediatr Drugs. 2013;15(1):59–70. - PubMed
    1. Madhi SA, Lopez P, Zambrano B, et al. Antibody persistence in pre-school children after hexavalent vaccine infant primary and booster administration. Hum Vaccin Immunother. 2018;15(3):658–668. - PMC - PubMed

MeSH terms

Substances